Immusol, Inc. Announces Research Collaboration With Peking University To Develop Therapeuic Compounds
10/19/2005 5:09:11 PM
SAN DIEGO, CA--(MARKET WIRE)--Aug 30, 2005 -- Immusol announced today that it has entered into a collaborative research agreement with leading researchers at Peking University (PKU), to identify, isolate and characterize patentable therapeutic compounds. Under the terms of the agreement, PKU will isolate and purify the active ingredients from a variety of natural plants and herbs with therapeutic potential. Immusol will characterize the biological activity of such ingredients using its proprietary assays for oncology, infectious disease, and other disease areas. Immusol will receive an exclusive worldwide license outside of China for any compounds developed by PKU under this collaboration. Additionally, rights for the compounds will be owned by PKU in China. Immusol will be solely responsible for moving compounds developed under this collaboration through both pre-clinical and human clinical trials in all territories outside of China.
comments powered by